Meet the Passionate
Individuals Behind Neurelis

Jenny Alonso joined Neurelis in 2020 as the General Counsel and Chief Compliance Officer. Prior to joining Neurelis, she served as General Counsel, Chief Compliance Officer, and Head of Human Resources at Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company in San Diego, California. At Prometheus, she implemented and managed the Compliance Program, all licensing and research studies, managed care arrangements, litigation, reimbursement matters, marketing issues, laboratory licensing, and billing matters. Further, she oversaw all HR-related matters, including performance reviews, compensation, and employee relations. Prior to joining Prometheus, Jenny was an associate at Latham & Watkins LLP for 8 years focusing primarily on healthcare-related matters, including fraud and abuse, compliance, reimbursement, and physician arrangements. Jenny received her BA from the University of California, San Diego, and graduated magna cum laude from the University of San Diego School of Law. She was admitted to the California State Bar in 1998.

Brittany Bradrick joined Neurelis in 2021 as the company’s Chief Financial Officer and had Chief Operating Officer & Chief Financial Officer added to her title in 2022. She joins the company with 25 years of experience in finance, strategy, and corporate development for life science companies, with both operational and advisory experience. Prior to joining Neurelis, Ms Bradrick was Chief Operating Officer & Chief Financial Officer at ViaCyte. She also previously served in strategy and corporate development positions for 10 years at Insulet and Abbott Diabetes Care and was an investment banker to the life science industry for 10 years at Piper Jaffray, Credit Suisse, and Chase Securities. Ms. Bradrick started her career as a Federal Reserve Bank Examiner. Ms. Bradrick earned an MBA from the Johnson Graduate School of Management at Cornell University and a BS in Business Administration from the University of Missouri.

Dr. Enrique Carrazana has over 25 years of experience in drug development and the pharmaceutical industry. Dr. Carrazana is a member of the board of directors of CND Life Sciences, Hawaii Biotech, Apex Labs, and the American Society for Experimental Neurotherapeutics. He currently serves as the Senior Vice President of Strategic Initiatives for Neurelis, Inc., where he is responsible for the scientific and clinical aspects of identifying, evaluating, negotiating and managing strategic business opportunities that further Neurelis’ corporate strategy. Dr. Carrazana was previously the Chief Medical Officer for Neurelis, a position he also held at Acorda Therapeutics. Dr. Carrazana also held various medical leadership roles at Novartis, where his last role was Vice President, Global Head Development Established Medicines Franchise, based in Basel, Switzerland. He was Director of the Epilepsy Center of Excellence at the Miami Veterans' Administration (VA) Hospital and Associate Professor of Neurology at the University of Miami, Miller School of Medicine. He has presented and published a wide range of research on various neurology topics. Dr. Carrazana received his medical degree from Harvard Medical School and completed his residency in neurology and fellowship in neurophysiology at the Harvard Longwood Neurology Program. He is a board-certified neurologist and Fellow of the American Epilepsy Society.

Craig Chambliss has 30 years invested in the biopharma and drug delivery arenas, with primary focus on rare diseases of the central nervous system (CNS) and epilepsy, in particular. He co-founded Neurelis in 2007, serving as CEO and President, and has raised over $300M in funding to progress the company to a fully integrated organization, from early-stage development through commercialization.

Mr. Chambliss was previously integral to the reengineering of NextWave Pharmaceuticals to a CNS focus as Chief Business Officer, raising $45M in Series C financing and culminating in the sale of NextWave to Pfizer for over $700M in 2012. Prior to NextWave and Neurelis, he led commercial operations at Questcor Pharmaceuticals, from 2005-2007, where he was integral in also engineering the transition to a CNS-focused company and establishing the commercial infrastructure to support the relaunch of Acthar^® Gel (repository corticotropin injection) to treat a rare epilepsy disorder in pediatrics.

Mr. Chambliss began his career in pharmaceutical sales at Bristol Myers Squibb and joined Alza Pharmaceuticals upon the launch of their commercial organization in 1994. While at Alza Pharmaceuticals, he served in various sales and marketing roles prior to joining Elan Pharmaceuticals, where he served as Director of Business Development for CNS assets. In 2001, along with other former Dura and Elan executives, Mr. Chambliss launched Xcel Pharmaceuticals, a CNS start-up focused on epilepsy and, primarily, the treatment of seizure emergencies. He led commercial operations and the successful launch of Diastat^® (diazepam rectal gel) until Xcel's acquisition by Valeant Pharmaceuticals in 2005 for $280M. Mr. Chambliss holds a BS in Finance and a BS in Accounting from Missouri State University.

Chuck DeWildt has served in leadership roles in Sales, Marketing, and Market Access in the pharmaceutical and biotechnology industry for more than 25 years. Chuck joined Neurelis initially as Sr. Vice President of Commercial and Market Access in early 2018 and was promoted to Chief Commercial Officer in 2019, overseeing the successful commercial buildout of Neurelis. His specific experience includes work in the CNS, respiratory, and oncology markets. Chuck joined Neurelis from Teva Pharmaceutical Industries Ltd, where he was Vice President of Market Access. He joined Teva in 2011 as part of their acquisition of Cephalon, where he was the Head of Market Access and Reimbursement. Chuck began his pharmaceutical career at DuPont and joined Cephalon in 1999.

Steve Jenner has more than 20 years of experience in the pharmaceutical and biotechnology industry with specific experience in the neurology, pain, glaucoma, and dermatology markets. Steve joined the Neurelis team in early 2019. He has served in various leadership roles in Sales, Marketing, Operations, and Managed Markets. Steve joined Neurelis from Zogenix, where he most recently served as the Vice President of Commercial for the U.S. Market. At Zogenix, he was responsible for leading the commercialization of multiple product launches, acting as commercial point person for all business development initiatives, and for the initial buildout of the rare disease business unit for the U.S. Market. Prior to Zogenix, he served as the Senior Vice President of Client Services at MedAccess Communications, and held marketing and product management leadership positions with companies such as Valeant Pharmaceuticals International, Allergan Pharmaceuticals, and Elan Pharmaceuticals, Inc. (which was acquired by Alkermes Plc.).

Thomas Liquard brings more than 15 years of organizational, corporate development, and commercial development leadership experience in the life sciences industry to Neurelis. Prior to joining Neurelis in 2017, Thomas served as CEO of Immuron Limited and was COO and then CEO of Alchemia Limited after spending seven years with Pfizer. At Pfizer, he held various commercial roles of increasing scope and responsibility, including roles in New Product Planning, Portfolio Decision & Analysis, U.S. Established Brands, and Emerging Markets. Thomas began his life sciences career as a Senior Consultant with the Frankel Group (now part of Oliver Wyman).

Stuart Madden has over 30 years of experience in the pharmaceutical industry working on drug development programs, from proof of concept through to commercialization for New Chemical Entity (NCE) and 505(b)(2) products that have encompassed small molecules, biologics, and combination products. Dr. Madden has worked with Neurelis since 2008, supporting the development of VALTOCO and, in July 2020, joined Neurelis as a full-time employee. Since 2003 and prior to joining Neurelis, Dr. Madden was Vice President of Scientific Affairs at ICON Clinical Research where his role was providing strategic consulting expertise to biotech and pharmaceutical clients in optimizing their development programs. From 1995 to 2003, Dr. Madden worked for Elan Corporation, a specialty drug delivery company specializing in the development and commercialization of controlled-release oral dosage forms. Earlier in his career, Dr. Madden worked in large pharma, including Mallinckrodt and Schering Plough. Dr. Madden received his BS degree in chemistry and his PhD in physical chemistry from the University of Wales, Swansea, UK, and spent 2 years as a postdoctoral fellow at San Diego State University, California. He is a Chartered Chemist and Fellow of the Royal Society of Chemistry and a past special government employee for FDA's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology.

Dr. Adrian L. Rabinowicz joined Neurelis in 2018 and is a board-certified neurologist and neurophysiologist with over 20 years of experience in global pharmaceutical and biotechnology companies. Prior to joining Neurelis, he served as Chief Medical Officer at Sancilio & Company, where he led all development programs, operational activities, and interactions with FDA and global regulatory authorities. Previously, Dr. Rabinowicz was Senior Vice President of Clinical Development and Medical Affairs at Acorda Therapeutics, and also spent over seven years with Bayer HealthCare Pharmaceuticals, holding various roles of increasing responsibility in different therapeutic areas, being involved in several regulatory filings. Dr. Rabinowicz received his medical degree from the Universidad Del Salvador, Buenos Aires, Argentina, and completed his residency in neurology at the University of Buenos Aires and his fellowship in Epilepsy and Neurophysiology at the University of Southern California, Los Angeles. He served as both an Assistant Professor of Neurology and the Co-Director of the USC Comprehensive Epilepsy program. Dr. Rabinowicz has received several national and international awards for his research, is a Fellow of the American Academy of Neurology, and has published over 85 peer-reviewed papers and several book chapters.

George Stuart was named Chief Operating Officer at Aegis Therapeutics LLC, a wholly owned subsidiary of Neurelis, in 2021. Previously, he served as Senior Vice President and Chief Financial Officer for Neurelis since 2011. Mr. Stuart has over 30 years of experience, including over 20 years of working in the specialty pharmaceutical and biotechnology industry. He has experience as a senior executive with both commercial- and development-stage pharmaceutical companies. Prior to his involvement with Neurelis, Mr. Stuart’s experience included management positions with Questcor Pharmaceuticals, where he was Senior Vice President and Chief Financial Officer; Xcel Pharmaceuticals, where he was Vice President and Chief Financial Officer and part of the founding team; Ligand Pharmaceuticals, where he was Director of Finance; and Deloitte, where he last held the position of Senior Manager. Mr. Stuart graduated from San Diego State University with a bachelor of science degree in accounting.